UniCAB
11 Nov 2020
Trial Summary
A Phase II Trial Of Single Agent Cabozantinib In Patients With Locally Advanced Or Metastatic Non-Clear Cell Renal Cell Carcinoma Post Immunotherapy Or Who Are Unsuitable For Immunotherapy
Acronym:
UniCAB
ACTRN/NCT /ethics:
NCT03685448
Scientific title:
A Phase II of Single Agent Cabozantinib in Patients With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma Post Immunotherapy or Who Are Unsuitable for Immunotherapy (ANZUP1802)
Sponsor / Cooperative group:
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Trial & Patient Characteristics
| Cancer Type | Kidney |
|---|---|
| Trial Type | Treatment |
| Phase | Phase II |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | Non-clear Cell Renal Cell Carcinoma |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2019-04-11 |
| Anticipated End Date | 2024-04-30 |
Participating Hospitals
| Hospital | Icon Cancer Centre Adelaide |
|---|---|
| Clinical Trial Coordinator | Sue Yeend |
| sue.yeend@icon.team | |
| Phone | 08 8292 2204 |
| Principal Investigator | Dr Francis Parnis |
| Recruitment Status | Recruiting |
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alison Richards |
| Alison.Richards@sa.gov.au | |
| Phone | 08 8206 4835 |
| Principal Investigator | Dr Ganessan Kichenadasse |
| Recruitment Status | Recruiting |